Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 8/20 | 0.53 |
| ▸ | CDK2 | P24941 | 15/20 | 0.52 |
| ▸ | CDK1 | P06493 | 7/20 | 0.52 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.51 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.51 |
| ▸ | CCNK | O75909 | 1/20 | 0.51 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.51 |
| ▸ | CDK7 | P50613 | 1/20 | 0.51 |
| ▸ | CDK9 | P50750 | 1/20 | 0.51 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.51 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3225072 | 1.00 | KCNH2 (0.53) | KCNH2CDK2CDK1MAPK8MAPK10 | |
| SCHEMBL3210701 | 0.94 | KCNH2 (0.52) | KCNH2CDK2CDK1MAPK8MAPK10 | |
| SCHEMBL3210714 | 0.94 | KCNH2 (0.52) | KCNH2CDK2CDK1MAPK8MAPK10 | |
| SCHEMBL3210708 | 0.94 | KCNH2 (0.52) | KCNH2CDK2CDK1MAPK8MAPK10 | |
| SCHEMBL3217699 | 0.87 | CDK2 (0.56) | KCNH2CDK2CDK1 | |
| SCHEMBL3217705 | 0.87 | CDK2 (0.56) | KCNH2CDK2CDK1 | |
| SCHEMBL4195695 | 0.87 | CDK2 (0.52) | KCNH2CDK2CDK1MAPK8 | |
| SCHEMBL3214604 | 0.87 | KCNH2 (0.52) | KCNH2CDK2CDK1 | |
| SCHEMBL3214611 | 0.87 | KCNH2 (0.52) | KCNH2CDK2CDK1 | |
| SCHEMBL4195833 | 0.83 | CDK2 (0.61) | KCNH2CDK2CDK1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100063049-A1 | 2-CARBOCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2010-03-11 | — | — | US | claimed |
| US-20100063049-A1 | 2-CARBOCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2010-03-11 | — | — | US | disclosed |
| EP-2029578-A1 | 2-CARBOCYCLOAMINO-4-IMIDAZ0LYLPYRIMIDINES AS AGENTS FOR THE INHBITION OF CELL PROLIFERATION | AstraZeneca AB (SE) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007138277-A1 | 2-CARBOCYCLOAMINO-4-IMIDAZ0LYLPYRIMIDINES AS AGENTS FOR THE INHBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063049-A1 | 2-CARBOCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHBITION OF CELL PROLIFERATION | MKI67, CCNI, CDK2 | KCNH2 2260/4885CDK2 3/4885CDK1 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.